Despite Covid-19 the Pivot Park Community managed to reach many successes in 2020. Pivot Park is very proud of the Community! Read here a short summary of the highlights of our Community members and click on the article to read more:

Month Company News
January Atro Medical Meniscus prosthesis from ATRO Medical receives FDA Breakthrough Device Designation
January Ardena Ardena has announced that it has been acquired by GHO Capital, the European specialist investor in healthcare
February PharmaCytics PharmaCytics wint Innovation for Health Award
March Citryll Citryll’s landmark paper published in Nature’s journal
April Innatoss Innatoss werkt hard aan een bloedtest om te kijken of mensen Covid-19 hebben gehad.
April Pivot Park Pivot Park investeert in strijd tegen corona
April InProcess LSP Tiofarma en InProcess-LSP werken samen aan Propofol nano-emulsie
May BioConnection Nieuwe productie faciliteit BioConnection
May Pivot Park Raamovereenkomst met IBN
May NTRC Novel Screening Assay NTRC / PPSC published in SLAS Discovery
May Pivot Park Screening Centre Novel Screening Assay for Arginase-1 Inhibitors published in SLAS Discovery
June PimBio PimBio receives a grant for feasibility study
July Citryll Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
August BG Legal BG.legal receives grant for AI knowledge platform
July Atro Medical EUROSTARS verstrekt financiering voor de eerste laterale meniscusprothese
September Synnafix Synnafix recognized with Best ADC Platform Technology Award
October Glycostem FDA grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma
November PharmaCytics PharmaCytics and Madam Therapeutics announce collaboration to develop a new class of oral anti-biotics.
November Lead Pharma Lead Pharma enters into a Research Collaboration with Roche
November Pivot Park Pharming will join Pivot Park
November Pivot Park Winners Venture Challenge 2020
November InProcess LSP InProcess-LSP contributed successfully to Covid-19 vaccine
December Glycostem Glycostem and Ghent University announced a license agreement on NK cell therapy technology
December Pivot Park Pivot Park haalt lectoraat Drug Discovery naar Oss

 

 

 

 

 

 

Back